BioNexus Gene Lab Corp. Proceeds from Grantors
BioNexus Gene Lab Corp. (BGLC) reported Proceeds from Grantors of $5.75 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromGrantors · last filed 2023-08-16
- 2023-06-30: Proceeds from Grantors 6 month $5.75M.
| Period end | Proceeds from Grantors 6 month |
|---|---|
| 2023-06-30 | $5.75M 10-Q · filed 2023-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |